All decreased cytokines in MS patients can be divided into two large groups: growth factors, VEGF (p = 3.6 × 10−4), PDGF-AB/BB (p = 1.1 × 10−6), TGF-a (p = 1.6 × 10−7), EGF (p = 7.7 × 10−18), and PDGF-AA (p = 2.6 × 10−15), and chemokines, IL-8/CXCL8 (p = 7.1 × 10−6), MDC/CCL22 (p = 5.5 × 10−3), MIP-1b/CCL4 (p = 1.5 × 10−3), and MCP-1/CCL2 (p = 4.1 × 10−3). This evidence concerns the gene CCL22 and myeloid sarcoma.